Background and aims: Patients with inflammatory bowel disease [IBD] are at increased risk for developing some types of neoplasia. Our aims were to determin the risk for cancer in patients with IBD and to describe the relationship with immunosuppressive therapies and clinical management after tumor diagnosis. Methods: Retrospective, multicenter, observational, 5-year follow-up, cohort study. Relative risk [RR] of cancer in the IBD cohort and the background population, therapeutic strategies, and cancer evolution were analyzed. Results: A total of 145 cancers were diagnosed in 133 of 9100 patients with IBD (global cumulative incidence 1.6% vs 2. 
Introduction
Patients with inflammatory bowel disease [IBD] are at increased risk for developing some types of neoplasia. 1, 2 Numerous studies have described a higher risk for colorectal cancer in patients with longstanding IBD but the relationship between IBD and extra-intestinal tumours is not well defined. Chronic inflammation associated with IBD can affect other organs besides the bowel and could be related to an increased risk for cancer in these areas. Latest publications in different populations across the world have found IBD patients to be at increased risk for different specific extra-intestinal tumors. 3, 4, 5 In particular, it has been reported that patients with Crohn's disease [CD] have an increased risk for developing cancer of the upper gastrointestinal tract, lung, urinary bladder, skin [squamous] and lymphoma. 6, 7 On the other hand, ulcerative colitis [UC] has been associated with an increased risk for hepatobiliary cancer and leukemia. 6, 8 IBD affects primarily young patients and the use of immunomodulators and anti-TNF drugs is frequent during the course of disease. These medications have also been associated with a variable risk for cancer. Thiopurines have been related to an increased risk for lymphoproliferative disorders and non-melanoma skin cancers. 9, 10 However, data regarding the relationship between anti-TNF-α drugs and cancer are more controversial on account of the frequent concomitant use of thiopurines in these patients. 11, 12, 13 Additionally, data published regarding management and cancer evolution, and the possibility of future immunosuppressant treatment after cancer, in these patients are scarce. 14 Therefore, the objectives of our study in a large series of IBD patients were: [1] to determine the incidence and characteristics of intestinal and extra-intestinal cancers affecting patients with IBD in our environment and to compare these with data in the background population; [2] to describe the clinical management of IBD patients and cancer; [3] to determine how the therapies prescribed for treatment of IBD can affect the risk for developing different cancers; and [4] to study the evolution and treatment of cancer in IBD patients.
Materials and Methods

Patients
We conducted an observational, retrospective, 5-year follow-up, cohort study. All cases of cancer diagnosed from January 2007 to the end of December 2011 in a multicenter cohort of patients with IBD [followed in 12 tertiary university hospitals in the Community of Madrid, Spain] were retrospectively included. The study was approved by the ethics committee of the steering center [Hospital Universitario de Fuenlabrada].
In each case, cancer was diagnosed by pathologists of the participating centers who classified the lesions according to the International Classification of Diseases for Oncology [ICD-O-3 histology codes].
Diagnosis of IBD was confirmed by routine clinical, radiologic, endoscopic, and histologic criteria. 15 Cumulative incidence and relative risk [RR] for the most common intestinal and extra-intestinal cancers were calculated in the IBD cohort and compared with the local background population of Madrid. Data corresponding to the baseline population were obtained using the tumor registry from the Community of Madrid. These registries contain all cases of cancer diagnosed during the 5-year follow-up period in the patients of each participating area.
Demographic data, time from diagnosis of IBD to occurrence of cancer, IBD treatment at time of cancer diagnosis, and therapeutic strategies for the management of patients after tumor diagnosis were collected in the IBD cohort. A possible association between IBD therapy and malignancy risk, and the treatment and evolution of cancer were also reviewed. Cancer recurrence was considered as the reappearance of cancer after treatment and after a period of time during which the tumor could not be detected, independently of the localization of the recurrent lesion. Cancer progression was defined as tumor spread or worsening clinical data. 
Statistical analysis
Results
Baseline characteristics of patients with inflammatory bowel disease and of the background population
A total of 145 cancers were diagnosed during the study period in 133 patients from a cohort of 9100 cases of IBD [4550 CD; 4326 UC; 224 indeterminate or unclassified colitis]. According to the type of IBD, 76 tumors were diagnosed in 66 patients with CD, 66 in 64 UC patients, and 3 in 3 patients with indeterminate colitis; 12 patients [9%] were diagnosed with two or more different cancers during follow-up. At the time of cancer diagnosis, the mean age of patients with IBD was 59 ± 14 years, 59% were males, 35% smokers, 20% had a family history of cancer, and 18% had had previous cancer before the study. Only in two instances was the previous cancer type the same as the cancer developed during the study, that is two patients with previous non-melanoma skin cancer developed a new non-melanoma skin cancer in a different site from the first tumor. The mean time-course of IBD until cancer development was 125 ± 113 months . Tumors were extra-intestinal in 82% of patients [n = 120]. Compared with the whole IBD population, mean age was higher in patients who developed cancer [59 ± 14 years vs 44 ± 14 years; p < 0.01]. Also, a trend to higher representation of males in the group of patients with tumors relative to the total IBD population was observed [59% vs 49% of males; p = 0.06]. No other differences were found in the remaining demographic characteristics analysed. All clinical and demographic characteristics of this cohort of patients with IBD and cancer diagnosis are shown in Table 1 .
The reference population of 12 participating centers consisted of 4 021 135 people. In this population, 97 583 tumors were diagnosed in the 5-year follow-up study period. Mean age of these cases was 64 ± 31 years. A 6.6% of patients had two or more tumors.
Incidence and characteristics of intestinal and extra-intestinal cancers in patients with inflammatory bowel disease and in the background population
The global cumulative incidence in the IBD group was 1.6% vs 2.4% in the local population; RR = 0.67; 95% CI: 0.57-0.78. When
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the cumulative incidences in CD and UC patients were compared, we found that the cumulative incidence in patients with CD was 1.7% vs 1.5% in the UC group; RR = 1.1; 0.79-1.52.
The most frequent neoplasms observed in the IBD cohort were skin, colorectal, breast, and lung tumors [ Table 2 ]. Compared with the background population, patients with IBD had a significantly increased RR for skin [non-melanoma type: 82% basal cell carcinoma; 18% squamous cell carcinoma; and 50% of lesions larger than 5 mm] and small bowel cancer [1 carcinoid and 2 adenocarcinomas]. However, the risk for colorectal, breast, lung, and prostate cancer was lower [p< 0.05] in patients with IBD than in the background population. The percentage of smokers in the group of patients who developed lung cancer was 50% smokers and 50% former smokers, and in the group who developed urinary bladder cancer was 37.5 smokers and 62.5% former smokers. Only one case of melanoma was observed in the cohort of patients with IBD [RR = 0.33; 0.076-3.82].
When the two different groups of IBD patients were compared separately with the background population, we found that patients with CD also had a significantly increased RR for non-melanoma skin and small bowel cancer [two CD patients with ileal involvement and diagnosis of small bowel adenocarcinoma, mean IBD duration: 108 months], and a significantly decreased RR for colorectal cancer [ Table 2 ]. On the other hand, patients with UC maintained an increased RR for non-melanoma skin cancer, but no further differences between UC patients and the local population were found for the remaining cancers [ Table 2 ].
Regarding hematological cancers, only one case each of nonHodgkin lymphoma; [RR = 0.13; 0.02-0.93] and myelodysplastic syndrome were observed in this series. None of these patients had received previously or were currently receiving immunosuppressive or anti-TNF-α drug therapy at the time of cancer diagnosis. Figure 1 ]. Globally, immunosuppressive IBD treatment was maintained in 19 of 48 patients after cancer diagnosis [39.6%] . The reason for continuing or discontinuing the therapy with immunosuppressant and/or anti-TNF-α drugs was in all cases determined by medical criteria, individualized based on the type of cancer and the evolution of IBD and in agreement with the oncology team.
Management and course of inflammatory bowel disease patients with associated cancer
In patients in whom immunosuppressive therapy was maintained, different types of tumors were observed. The most common cancers were: non-melanoma skin cancer [n = 4]; urinary bladder cancer [n = 4]; cervical cancer [n = 3]; and ovarian cancer [n = 2]. The characteristics of these patients, type of treatment maintained, and tumor evolution are shown in Table 3 . There were two cases on azathioprine therapy in which lung cancer was diagnosed, both patients dying a short period after the tumor diagnosis. In the remaining patients on immunosuppressive and/or anti-TNF-α drugs [n = 27], the treatment was withdrawn, and in three of these cases a therapy was reintroduced or incorporated later in agreement with the oncology team. The evolution of these three cases was as follows: a breast carcinoma with azathioprine reintroduction 3 years after tumor with no cancer progression; a non-melanoma skin tumor in remission for more than 3 years after thiopurine introduction; and a breast ductal carcinoma [with previous IBD therapy with adalimumab before cancer diagnosis] in whom methotrexate was prescribed, maintaining cancer remission after 5 years' follow-up. According to cancer type, immunosuppressive and/or anti-TNF-α drug treatment was discontinued in all cases of lung [four non-small cell lung cancers] and kidney cancer [two clear-cell carcinoma, and one papillary cell carcinoma], and under no circumstances was re-introduced later. Also, there were six cases [one vocal cord squamous cell carcinoma, one colon adenocarcinoma, one urinary bladder cancer, one papillary thyroid carcinoma, one non-melanoma skin cancer, and one breast ductal carcinoma]. These were without IBD treatment at cancer diagnosis [n = 4] or with immunosuppressive and/or anti-TNF-α drug treatment which was maintained after tumor diagnosis [one azathioprine; one adalimumab treatment]. The six required added thiopurines and/or anti-TNF-α drug treatment [two with: adalimumab; two with azathioprine; one with azathioprine and infliximab; and one with methotrexate and adalimumab] during follow-up due to IBD flares, with cancer remission in all cases.
Regarding patients with non-melanoma skin cancer diagnoses [n = 23], 18 were not receiving treatment for their IBD at time of cancer, four were on inmunomodulator therapy [two azathioprine, two metrotrexate] and one patient was on combined therapy. Methotrexate was withdrawn in one case, whereas the remaining patients maintained their therapy, with cancer remission [ Table 3 The percentage of patients who died was not different in patients who maintained the immunosuppressive and/or biologic treatment after tumor diagnosis compared with patients in whom this treatment was stopped or who were not exposed to these drugs at the time of tumor diagnosis [5% vs 8%; p = 0.29, and 5% vs 19%; p = 0.13, respectively].
Evolution and treatment of cancer in patients with inflammatory bowel disease
Discussion
In our series, the overall incidence of cancer was not higher in the IBD group compared with the local population. However, our patients with IBD had an increased risk for non-melanoma skin cancer, as previously described. 16, 17, 18 In particular, previous studies have reported that the combination of thiopurines and ultraviolet A light can result in definitive mutations of epithelial skin cells, that persist even after stopping treatment. 9, 19, 20, 21 18 Regarding the effect of anti-TNF α agents, data are controversial; some studies have found that anti-TNF-α use is associated with a higher risk for non-melanoma skin cancer but other authors suggest this therapy could act as a potential cancer inhibitor. 22, 23 In our study, the increased risk found for non-melanoma cancers was not associated with thiopurine or anti-TNF-α drug use, so it could therefore be advisable to recommend that all patients with IBD protect themselves against UV radiation [sunscreen with ultraviolet A and B protection]. Non-melanoma skin cancers are rarely invasive, have a high survival rate in absence of metastasis, and their resection is quite effective. 21 In our study almost all patients [except one patient in whom methotrexate was withdrawn] maintained the immunosuppressive and/or anti-TNF-α drug before and after surgical excision, with no cancer recurrence during follow-up. Taking into account the results obtained, once non-melanoma skin cancer has been diagnosed, maintaining IBD treatment could be a reasonable option for these patients, always considering the oncologist's opinion.
Regarding melanoma risk, we only detected one case in our study [without inmunosuppresive or anti-TNF-α drug therapy] and the RR was similar to that in the background population. Data about the risk for melanoma in patients with IBD have been discussed extensively, and some studies have found an increased risk for these patients. 24 In the CESAME cohort study, the risk for melanoma among the overall IBD population was similar to that observed in the general population [standardized incidence ratio 0.64; 0.17-1.63]. 25 In the latest meta-analysis published by Singh et al., the authors concluded that IBD is related to an increased risk for melanoma [RR 1.37; 1.10-1.70] but they did not find association with thiopurines or anti-TNF treatment. 24 In patients with IBD, an increased risk for hematological malignancies has been described. 26 The CESAME group observed a 5-fold increased risk for lymphoproliferative disorders in patients receiving thiopurines, compared with patients who had never been exposed to these drugs. 10 Recently, the same result has been obtained by Kotlyar et al. in their meta-analysis study, but the increased risk for lymphoma in patients taking thiopurines does not appear to persist after discontinuation of therapy. 27 Combined therapy seems to increase the lymphoma risk, but the increased risk may be due to the effect of thiopurines essentially, more tthan to an influence of the anti-TNF-α therapy. 13 In addition, Osterman et al. found that CD patients treated with an immunomodulator and adalimumab had an increased risk for malignancy compared with the general population, whereas adalimumab monotherapy did not increase the risk. 28 In our series, approximately one-third of patients were on thiopurine treatment and none development lymphoma. Taking into account that lymphoma incidence is low [the expected rate of non-Hodgkin cancer is about 1.9 per 10 000 patient-years], 29 possibly a longer period of time would be necessary to observe cases of this malignancy.
The present cohort study found that patients with CD have an increased risk for developing small bowel cancer. The two small bowel adenocarcinomas observed in our series were diagnosed in CD patients with ileal involvement and longstanding disease. Small bowel cancers are uncommon tumors and they only account for 3% to 6% of all gastrointestinal neoplasms. 30 Although a causal relationship between CD and this type of cancer is still being elucidated, some authors have identified CD as predisposing to an increase in risk for small bowel cancer. 1, 31 Although many studies have shown increased rates of colorectal cancer in patients with IBD, currently the reported risks are lower than those published before the 2000s. 32, 33, 34 These recent data are consistent with our results; in the present study the risk for colorectal cancer in patients with IBD was not higher than in the background population. Some authors have found that only patients with long-standing, extensive IBD affecting the colon or diagnosed at a young age have higher risk for colorectal cancer. 2, 34 The reasons why the risk is currently declining could be related to effective screening programs and the improvement of therapy options. 35, 36 In our study, the RR of malignancy was lower in patients on immunosuppressive or anti-TNF-α medication than in patients without these therapies. Current studies have reported how immunosuppressant therapy can reduce the risk for inflammation-related cancers, for example colorectal cancer, via their anti-inflammatory effects. Moreover, the incidences of different types of tumors reported in the Therapy, Resource, Evaluation, and Assessment Tool (TREAT) registry have been similar in patients who received infliximab and those who received other treatments.
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Data about clinical management of IBD patients after cancer diagnosis and data about evolution of cancer are scarce. There are no guidelines available yet and the decision on continuation of therapy has to be taken case by case; most experience derives from transplant studies.
Regarding the recurrence of cancer in transplant patients, the risk for developing cancer recurrence or a new cancer is higher in patients on thiopurines, especially with respect to non-melanoma skin cancer and lymphomas [transplantation could be contraindicated or postponed in a patient with a recent cancer diagnosis]. 37, 38 Concerning anti-TNF-α drugs, data obtained in rheumatoid arthritis suggest a similar risk for recurrent or new malignancy in patients exposed to anti-TNF-α compared with patients not so exposed. 39 Although there are more data supporting a possible association between cancer recurrence and thiopurines than between cancer recurrence and anti-TNF-α therapies, in our study thiopurine therapy was maintained in half of the IBD patients whereas anti-TNF-α drugs were withdrawn in most cases, showing reluctance to use anti-TNF-α once the cancer had been diagnosed.
The present series revealed that patients who maintained treatment [globally more than one-third of patients maintained the immunosuppressive and/or anti-TNF-α treatment after the tumor was diagnosed] did not appear to have a worse prognosis of cancer and tumour progressionand this seems to be independent of the treatment used to control IBD. However, for the time being we cannot recommend maintenance of immunosuppressant therapy in a specific type of tumor, and it is necessary to individualize management in agreement with the oncology team. In patients in whom immunosuppressant therapy was stopped after cancer diagnosis, this could be reintroduced later, after a reasonable period of time. How long should this period be is still uncertain and further research is needed to establish it. Taking into account studies in transplant patients, the recurrence risk decreases with time 14 ; but, at the moment, clinicians must evaluate the IBD evolution and consider oncologist recommendations before restarting immunosuppressant/anti-TNF-α treatment.
Finally, the observations obtained in the present study should be considered with caution on account of the limited duration of follow-up and the time of treatment, so that an increased risk for malignancy in the long term cannot be excluded. Also, data corresponding to the baseline population were obtained using the tumor registry from our area which can have some limitations, including the possibility of cancer diagnosis in a center outside our community or outside the public health system. We estimate that the number of patients diagnosed under these circumstances is low, and we think that these limitations do not allow for significancein the variation in the data presented.
Conclusions
The overall risk for cancer was not significantly increased among our patients with IBD. However, they were at a higher risk for developing non-melanoma skin cancer. The risk was not related to thiopurine and/or anti-TNF-α use. Patients with CD showed an increased risk for developing small bowel cancer, supporting a possible relationship between CD and this type of cancer. We did not find a higher risk for colorectal cancer, melanoma, or lymphoproliferative disorders. Immunomodulator therapy is maintained in half of the IBD patients after a cancer diagnosis. In contrast, anti-TNF-α drugs are withdrawn in most cases. An association between these drugs and a higher cancer risk was not found in our series. Patients who continued treatment did not have a worse prognosis of cancer. Therefore, maintaining these therapies or reintroducing them could be possible in selected patients, always if in agreement with the oncologist's recommendations.
